Paper41540320
A novel murine model of LITT for glioblastoma reveals tumor reduction, BBB permeabilization, and drug delivery via ThermoDox®.
Athukuri P and 10 others. Drug Deliv Transl Res, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. A novel murine model of LITT for glioblastoma reveals tumor reduction, BBB permeabilization, and drug delivery via ThermoDox®. Papers, record 41540320. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41540320
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A novel murine model of LITT for glioblastoma reveals tumor reduction, BBB permeabilization, and drug delivery via ThermoDox®.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Blood-Brain Barrier | Major topic |
| Brain Neoplasms | Major topic |
| Doxorubicin | Major topic |
| Glioblastoma | Major topic |
| Laser Therapy | Major topic |
| Antibiotics, Antineoplastic | Major topic |
| Hyperthermia, Induced | Major topic |
| Animals | |
| Cell Line, Tumor | |
| Disease Models, Animal | |
| Drug Delivery Systems | |
| Mice | |
| Mice, Inbred C57BL | |
| Humans |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R21 NS123589 | NINDS NIH HHS | United States | R21NS123589 | PubMed |
| R21NS123589 | NINDS NIH HHS | United States | R21NS123589 | PubMed |
Source NIH RePORTER
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16091763 | Resistance to tumour challenge after tumour laser thermotherapy is associated with a cellular immune response. | Br J Cancer | 2005 | https://conductscience.org/library/papers/16091763 | PubMed |
| 2 | 22178041 | Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. | J Vasc Interv Radiol | 2012 | https://conductscience.org/library/papers/22178041 | PubMed |
| 3 | 7693418 | Epirubicin. Clinical pharmacology and dose-effect relationship. | Drugs | 1993 | https://conductscience.org/library/papers/7693418 | PubMed |
| 4 | 35104794 | Syngeneic murine glioblastoma models: reactionary immune changes and immunotherapy intervention outcomes. | Neurosurg Focus | 2022 | https://conductscience.org/library/papers/35104794 | PubMed |
| 5 | 36632307 | Survival and quality of life analysis in glioblastoma multiforme with adjuvant chemoradiotherapy: a retrospective study. | Rep Pract Oncol Radiother | 2022 | https://conductscience.org/library/papers/36632307 | PubMed |
| 6 | 34205567 | Measurement of Ex Vivo Liver, Brain and Pancreas Thermal Properties as Function of Temperature. | Sensors (Basel) | 2021 | https://conductscience.org/library/papers/34205567 | PubMed |
| 7 | 23560574 | Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma: clinical article. | J Neurosurg | 2013 | https://conductscience.org/library/papers/23560574 | PubMed |
| 8 | 35489652 | Laser ablation: Heating up the anti-tumor response in the intracranial compartment. | Adv Drug Deliv Rev | 2022 | https://conductscience.org/library/papers/35489652 | PubMed |
| 9 | 29849513 | Evans Blue Dye: A Revisit of Its Applications in Biomedicine. | Contrast Media Mol Imaging | 2018 | https://conductscience.org/library/papers/29849513 | PubMed |
| 10 | 10969790 | Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. | Cancer Res | 2000 | https://conductscience.org/library/papers/10969790 | PubMed |
| 11 | 24561446 | Thermal ablation of tumours: biological mechanisms and advances in therapy. | Nat Rev Cancer | 2014 | https://conductscience.org/library/papers/24561446 | PubMed |
| 12 | 10728674 | A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. | Cancer Res | 2000 | https://conductscience.org/library/papers/10728674 | PubMed |
| 13 | 22952218 | Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. | Cancer Res | 2012 | https://conductscience.org/library/papers/22952218 | PubMed |
| 14 | 34554269 | Adaptation of laser interstitial thermal therapy for tumor ablation under MRI monitoring in a rat orthotopic model of glioblastoma. | Acta Neurochir (Wien) | 2021 | https://conductscience.org/library/papers/34554269 | PubMed |
| 15 | 30202239 | Sulbactam-enhanced cytotoxicity of doxorubicin in breast cancer cells. | Cancer Cell Int | 2018 | https://conductscience.org/library/papers/30202239 | PubMed |
| 16 | 32672122 | The use of laser interstitial thermal therapy in the treatment of brain metastases: a literature review. | Int J Hyperthermia | 2020 | https://conductscience.org/library/papers/32672122 | PubMed |
| 17 | 32793888 | Laser interstitial thermal therapy. | Neurooncol Adv | 2020 | https://conductscience.org/library/papers/32793888 | PubMed |
| 18 | 32666049 | Therapeutic enhancement of blood-brain and blood-tumor barriers permeability by laser interstitial thermal therapy. | Neurooncol Adv | 2020 | https://conductscience.org/library/papers/32666049 | PubMed |
| 19 | 27861323 | Stereotactic Laser Interstitial Thermal Therapy for Recurrent High-Grade Gliomas. | Neurosurgery | 2016 | https://conductscience.org/library/papers/27861323 | PubMed |
| 20 | 9738985 | Antitumor immunity induction by intracellular hyperthermia using magnetite cationic liposomes. | Jpn J Cancer Res | 1998 | https://conductscience.org/library/papers/9738985 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42978966 | Intranasal nano-immunotherapy for glioma: bypassing the blood-brain barrier, reprogramming the immune microenvironment, and bridging preclinical validation. | Front Immunol | 2026 | https://conductscience.org/library/papers/42978966 | PubMed |
| 42883298 | Recent Advances in Small-Molecule-Based Nanovectors for the Treatment of Colorectal Cancer. | Molecules | 2026 | https://conductscience.org/library/papers/42883298 | PubMed |
| 42265512 | Laser interstitial thermal therapy (LITT) for brain metastases: a systematic review and pooled analysis of Efficacy/Safety and the role of combination treatments. | J Neurooncol | 2026 | https://conductscience.org/library/papers/42265512 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41540320
GET https://conductscience.org/api/papers/v1/41540320/references?page=2